% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Riemenschneider:153422,
      author       = {Riemenschneider, Markus J. and Fischer, Josephine and
                      Grassow-Narlik, Maja and Mawrin, Christian and Deimling,
                      Andreas von and Pietsch, Torsten and Reifenberger, Guido and
                      Mueller, Wolf C. and Sommer, Clemens J. and Dietel, Manfred
                      and Zoubaa, Saida and Lorenz, Julia and Rothhammer-Hampl,
                      Tanja},
      title        = {{Q}uality assurance in neuropathology: {E}xperiences from
                      the round robin trials on {IDH} mutation and {MGMT} promoter
                      methylation testing launched by the {Q}uality {A}ssurance
                      {I}nitiative {P}athology ({Q}u{IP}) in 2018 and 2019},
      journal      = {Clinical neuropathology},
      volume       = {39},
      number       = {09},
      issn         = {0722-5091},
      address      = {Deisenhofen, München},
      publisher    = {Dustri-Verl.},
      reportid     = {DZNE-2020-01419},
      pages        = {203 - 211},
      year         = {2020},
      abstract     = {We here report on the first neuropathological round robin
                      trials initiated by the Quality Assurance Initiative
                      Pathology (QuIP) in Germany in the years 2018 and 2019.
                      Testing services as external laboratory controls were
                      offered for IDH1-R132H immunohistochemistry in 2018 followed
                      by a molecular trial for IDH1 and IDH2 mutations in 2019
                      including the rare mutational variants. Also in 2019, a
                      trial on MGMT promoter methylation testing was offered. On a
                      national scale, trial offers were well received with around
                      40 participating institutions. The international
                      announcement of the molecular IDH1/IDH2 mutational trial
                      achieved only moderate European outspread. Success rates in
                      all three trials were excellent (IDH1-R132H
                      immunohistochemistry 2018: $94\%,$ 18 out of 20 possible
                      points required; IDH1/IDH2 mutational status 2019: $100\%,$
                      19 out of 20 possible points required; MGMT promoter
                      methylation 2019: $94\%,$ 19 out of 20 possible points
                      required) indicating that quality standards are high in the
                      broad majority of the institutions. Trial participation also
                      involved filling in a questionnaire asking for background
                      information on local testing procedures. We here present a
                      first assessment of the information collected providing
                      unique insights in the landscape of molecular testing in
                      neuropathology. Derived from this information we identify
                      future challenges and provide an outlook on the development
                      of quality assurance in the field of neuropathology.},
      cin          = {Brainbank Unit Bonn},
      ddc          = {610},
      cid          = {I:(DE-2719)1011009},
      pnm          = {345 - Population Studies and Genetics (POF3-345)},
      pid          = {G:(DE-HGF)POF3-345},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.5414/NP301278},
      url          = {https://pub.dzne.de/record/153422},
}